JAK-inhibitors and risk on serious viral infection, venous thromboembolism and cardiac events in patients with rheumatoid arthritis: A protocol for a prevalent new-user cohort study using the Danish nationwide DANBIO register

• Maria Luisa Faquetti ,

  Contributed equally to this work with: Maria Luisa Faquetti, Enriqueta Vallejo-Yagüe

  Roles Methodology, Writing – original draft, Writing – review & editing

  Affiliation Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland

  https://orcid.org/0000-0002-5990-3322

  ⨯
• Enriqueta Vallejo-Yagüe ,

  Contributed equally to this work with: Maria Luisa Faquetti, Enriqueta Vallejo-Yagüe

  Roles Methodology, Writing – original draft, Writing – review & editing

  Affiliations Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland, Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland

  https://orcid.org/0000-0002-5911-2037

  ⨯
• René Cordtz,

  Roles Software, Writing – review & editing

  Affiliations Center of Rheumatic Research Aalborg, (CERRA), Aalborg University Hospital, Aalborg, Denmark, DANBIO Register, Aalborg, Denmark

  ⨯
• Lene Dreyer ,

  Roles Funding acquisition, Resources, Writing – review & editing

  ¶‡ LD and AMB also contributed equally to this work.

  Affiliations Center of Rheumatic Research Aalborg, (CERRA), Aalborg University Hospital, Aalborg, Denmark, DANBIO Register, Aalborg, Denmark, Clinical Institute, Aalborg University, Aalborg, Denmark

  https://orcid.org/0000-0002-5156-2922

  ⨯
• Andrea M. Burden

  Roles Conceptualization, Funding acquisition, Resources, Writing – review & editing

  * E-mail: andrea.burden@pharma.ethz.ch

  ¶‡ LD and AMB also contributed equally to this work.

  Affiliations Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada

  https://orcid.org/0000-0001-7082-8530

  ⨯